Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to two new employees. The Compensation Committee approved stock options to purchase 7,400 shares at $17.47 per share (the closing price on December 9, 2024) and restricted stock units for 3,700 shares. These equity awards were granted under the Company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.
Arcus Biosciences (NYSE:RCUS), una società biofarmaceutica in fase clinica focalizzata sulle terapie per il cancro, ha concesso premi azionari a due nuovi dipendenti. Il Comitato per la Retribuzione ha approvato opzioni azionarie per l'acquisto di 7.400 azioni a $17,47 per azione (il prezzo di chiusura del 9 dicembre 2024) e unità azionarie vincolate per 3.700 azioni. Questi premi azionari sono stati concessi nell'ambito del Piano di Induzione 2020 della Società, stabilito ai sensi della 'eccezione di induzione' della Regola 303A.08 del Manuale delle Società Quotabili di NYSE.
Arcus Biosciences (NYSE:RCUS), una empresa biofarmacéutica en etapa clínica centrada en terapias contra el cáncer, ha otorgado premios de capital a dos nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones para adquirir 7,400 acciones a $17.47 por acción (el precio de cierre del 9 de diciembre de 2024) y unidades de acciones restringidas por 3,700 acciones. Estos premios de capital se otorgaron bajo el Plan de Inducción 2020 de la Compañía, que fue establecido bajo la 'excepción de inducción' de la Regla 303A.08 del Manual de Compañías Cotizadas de NYSE.
Arcus Biosciences (NYSE:RCUS)는 암 치료에 집중하는 임상 단계의 생명공학 회사로, 두 명의 새로운 직원에게 지분 보상을 부여했습니다. 보상 위원회는 2024년 12월 9일 마감 가격인 주당 $17.47에 7,400주의 주식을 구매할 수 있는 주식 옵션과 3,700주의 제한 주식단위를 승인했습니다. 이러한 지분 보상은 NYSE 상장 회사 매뉴얼 규칙 303A.08의 '유인 예외'에 따라 설립된 회사의 2020 유인 계획에 따라 부여되었습니다.
Arcus Biosciences (NYSE:RCUS), une société bio-pharmaceutique en phase clinique spécialisée dans les thérapies contre le cancer, a accordé des récompenses en actions à deux nouveaux employés. Le Comité de rémunération a approuvé des options d'achat d'actions pour acquérir 7 400 actions au prix de 17,47 $ par action (le prix de clôture au 9 décembre 2024) et des unités d'actions restreintes pour 3 700 actions. Ces récompenses en actions ont été accordées dans le cadre du Plan de stimulation 2020 de la Société, établi en vertu de l' 'exception de stimulation' de la Règle 303A.08 du Manuel des sociétés cotées en bourse de la NYSE.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Krebstherapien konzentriert, hat zwei neuen Mitarbeitern Aktienbelohnungen gewährt. Der Vergütungsausschuss genehmigte Aktienoptionen zum Kauf von 7.400 Aktien zu je 17,47 $ pro Aktie (der Schlusskurs am 9. Dezember 2024) sowie beschränkte Aktieneinheiten für 3.700 Aktien. Diese Aktienbelohnungen wurden im Rahmen des Induktionsplans 2020 des Unternehmens gewährt, der unter der 'Induktionsausnahme' gemäß Regel 303A.08 des NYSE-Handbuchs für börsennotierte Unternehmen eingerichtet wurde.
- None.
- None.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210976574/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
What equity awards did Arcus Biosciences (RCUS) grant to new employees in December 2024?
What was the exercise price for RCUS stock options granted on December 9, 2024?
Under which plan were the RCUS equity awards granted in December 2024?
